GlassScriptPhysician profile
Hannah P Johnk
NPI 1225479181
$2,635.77
in general payments reported to CMS, 2019-2025
28 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $262 · 2021: $513 · 2022: $358 · 2023: $549 · 2024: $179 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,190.39 | 2019-2025 | Viaflow, Variax, Augment Injectable |
| Musculoskeletal Transplant Foundation INC. | $280.42 | 2019-2022 | |
| Amgen INC. | $211.34 | 2019-2022 | |
| Depuy Synthes Sales INC. | $146.67 | 2019-2025 | Motoband |
| Novo Nordisk INC | $97.38 | 2019-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $91.06 | 2019-2022 | |
| Pfizer INC. | $89.31 | 2021-2023 | |
| Lilly USA, LLC | $62.22 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $61.53 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $41.53 | 2019-2022 | |
| Genentech USA, INC. | $37.82 | 2020 | |
| Novartis Pharmaceuticals Corporation | $32.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.87 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $27.17 | 2023 | Prehevbrio |
| Organogenesis INC. | $23.68 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23.27 | 2021 | |
| Eisai INC. | $21.52 | 2021 | |
| Integra Lifesciences Corporation | $20.76 | 2021 | |
| Amarin Pharma, INC. | $19.99 | 2021 | |
| Seqirus USA INC | $19.83 | 2022 | |
| Bioxcel Therapeutics, INC. | $17.90 | 2023 | Igalmi |
| Takeda Pharmaceuticals U.S.A., INC. | $14.80 | 2020 | |
| Pacira Therapeutics, INC. | $13.94 | 2020 | |
| Jazz Pharmaceuticals INC. | $13.04 | 2021 | |
| Smith+Nephew, INC. | $12.05 | 2021 | |
| Treace Medical Concepts, INC. | $12.03 | 2022 | |
| Merck Sharp & Dohme LLC | $11.81 | 2022 | |
| Biogen, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Johnk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.